Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Mean weight loss of 19.2% at 6 mg with no plateau in 48-week Phase 3 trial – – Favorable safety profile consistent with other ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

China-based Jiangsu Hengrui Pharma and US start-up Kailera Therapeutics, which is advancing a broad pipeline of ...

U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body weight in a late-stage study in ...

A glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist developed by Jiangsu Hengrui Pharmaceuticals Co. Ltd. and licensed by Kailera Therapeutics Inc. has ...

Verona Pharma VRNA has signed a definitive agreement with pharma bigwig Merck MRK. Per the terms, the pharma giant will ...

SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3 (local time). Hengrui Pharma delivered a strong international presence, featuring 15 ...